Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra A, Grunstein RR, Fietze I, et al. New England Journal of Medicine 2024;391:1193-1205.
What it found
Two trials in adults with moderate-to-severe obstructive sleep apnoea and obesity, one without and one with CPAP. Breathing interruptions per hour (apnea-hypopnea index) fell by 25.3 vs 5.3 events per hour with placebo in the first trial, and by 29.3 vs 5.5 in the second.
Limitations
52 weeks. The benefit is thought to come largely from weight loss; whether it lasts after stopping was not tested.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.